MX368505B - Uso de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio o una sal farmaceuticamente aceptable del mismo en la prevencion y tratamiento de diabetes. - Google Patents

Uso de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio o una sal farmaceuticamente aceptable del mismo en la prevencion y tratamiento de diabetes.

Info

Publication number
MX368505B
MX368505B MX2016003347A MX2016003347A MX368505B MX 368505 B MX368505 B MX 368505B MX 2016003347 A MX2016003347 A MX 2016003347A MX 2016003347 A MX2016003347 A MX 2016003347A MX 368505 B MX368505 B MX 368505B
Authority
MX
Mexico
Prior art keywords
dimethylpropan
carboxy
ethyl
pharmaceutically acceptable
aminium
Prior art date
Application number
MX2016003347A
Other languages
English (en)
Other versions
MX2016003347A (es
Inventor
Ivars Kalvins
Ilmars Stonans
Maija Dambrova
Edgars Liepins
Cirule Helena
Misane Ilga
Makarova Elina
Original Assignee
Grindeks Jsc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grindeks Jsc filed Critical Grindeks Jsc
Publication of MX2016003347A publication Critical patent/MX2016003347A/es
Publication of MX368505B publication Critical patent/MX368505B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se relaciona con el uso de 3-Carboxi-N-etil-N,N-dimetilpropan-1-aminio y su sal farmacéuticamente aceptable para disminuir los niveles de plasma en sangre de insulina y glucosa.
MX2016003347A 2013-09-26 2014-09-15 Uso de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio o una sal farmaceuticamente aceptable del mismo en la prevencion y tratamiento de diabetes. MX368505B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13186201 2013-09-26
PCT/IB2014/064514 WO2015044828A1 (en) 2013-09-26 2014-09-15 Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes

Publications (2)

Publication Number Publication Date
MX2016003347A MX2016003347A (es) 2016-06-24
MX368505B true MX368505B (es) 2019-10-04

Family

ID=49231372

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016003347A MX368505B (es) 2013-09-26 2014-09-15 Uso de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio o una sal farmaceuticamente aceptable del mismo en la prevencion y tratamiento de diabetes.

Country Status (9)

Country Link
CN (1) CN105530929B (es)
AR (1) AR099638A1 (es)
BR (1) BR112016004211B1 (es)
CA (1) CA2924682C (es)
JO (1) JO3333B1 (es)
MX (1) MX368505B (es)
TN (1) TN2016000064A1 (es)
WO (1) WO2015044828A1 (es)
ZA (1) ZA201600894B (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2067474A1 (en) * 2007-12-05 2009-06-10 Grindeks, a joint stock company Medical use of 3-(2,2,2-trimethylhydrazinium) propionate hydrogen fumarate
LV14345B (lv) * 2009-10-22 2011-07-20 Grindeks, A/S 4-[Etil(dimetil)amonija]butanoāts un tā izmantošana kardiovaskulāro slimību ārstēšanai
AU2012247467B2 (en) 2011-04-27 2016-07-28 Grindeks, A Joint Stock Company Use of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease

Also Published As

Publication number Publication date
ZA201600894B (en) 2017-05-31
BR112016004211B1 (pt) 2022-09-06
CN105530929B (zh) 2018-03-02
BR112016004211A2 (es) 2017-08-01
WO2015044828A1 (en) 2015-04-02
CA2924682A1 (en) 2015-04-02
CA2924682C (en) 2018-02-27
MX2016003347A (es) 2016-06-24
JO3333B1 (ar) 2019-03-13
CN105530929A (zh) 2016-04-27
TN2016000064A1 (en) 2017-07-05
AR099638A1 (es) 2016-08-10

Similar Documents

Publication Publication Date Title
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
PH12015500115A1 (en) Glucagon analogues
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
HK1223529A1 (zh) 針對患有糖尿病的人的低血糖治療
MX2016011881A (es) Medicamento de peptido en polvo seco.
MY193671A (en) Dihydropyrimidin-2-one compounds and medical use thereof
WO2014152754A3 (en) Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
MX368505B (es) Uso de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio o una sal farmaceuticamente aceptable del mismo en la prevencion y tratamiento de diabetes.
MX2013009456A (es) Compuestos de azufre aromaticos sustituidos y metodos para su uso.
RS55061B1 (sr) Novi derivati amino-pirolina i njihova upotreba u prevenciji i/ili lečenju metaboličkog sindroma
MX2013012551A (es) Uso de sales de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio en el tratamiento de enfermedades cardiovasculares.
PH12015500306A1 (en) Arry-520 for use in treating cancer in a patient with low aag
SG10201809418VA (en) New administration routes of insulin, insulin analogs or derivatives of insulin
PL2852400T3 (pl) Analog insuliny lub jego farmaceutycznie dopuszczalna sól, kompozycja farmaceutyczna o przedłużonym działaniu terapeutycznym, zastosowanie analogu insuliny, sposób dawkowania oraz sposób leczenia cukrzycy
AU2014903587A0 (en) Regulation of a blood glucose level in a patient with diabetes
PH12015500178B1 (en) Injectable supersaturated acetaminophen solution for spinal administration
IN2014DE00818A (es)
UA97741C2 (ru) Способ восстановления кожных покровов при глубоких распространенных ожогах микроаутодермотрансплантатами
GB201304462D0 (en) Therapeutic vaccine for treatment of type 2 diabetes and impaired glucose tolerance
UA74770U (ru) Способ лечения больных с хронической патологией гепатобилиарной системы на фоне синдрома повышенной усталости
UA74052U (ru) Способ профилактики боковых грыж живота у больных с функционирующей колостомой и вентральной грыжей
UA79303U (ru) Применение таурина как средства стабилизации концентрации итраконазола в плазме крови при лечении грибковых заболеваний
UA84195U (ru) Способ лечения гриппа у взрослых
LV14497A (lv) Sastāvs tahikardijas novēršanai, ārstējot sāpes sirdī
UA73001U (ru) Способ лечения больных туберкулезом легких в сочетании с ВИЧ-инфекцией/СПИДом

Legal Events

Date Code Title Description
FG Grant or registration